BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting ThermoStem® Metabolic Disease Program
Portfolio Pulse from
BioRestorative Therapies has received a Notice of Allowance for a new patent covering cGMP manufacturing processes for its ThermoStem® Metabolic Disease Program, expected to provide protection until April 29, 2040.
December 05, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioRestorative Therapies has been granted a Notice of Allowance for a patent related to its ThermoStem® Metabolic Disease Program, which will protect its cGMP manufacturing processes until 2040.
The new patent provides long-term protection for BioRestorative's manufacturing processes, which is crucial for maintaining competitive advantage and potential revenue streams in the metabolic disease market. This is likely to positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100